Denvax Cellular Therapies Profile
Key Indicators
- Authorised Capital ₹ 1.10 Cr
as on 31-07-2024
- Paid Up Capital ₹ 1.10 Cr
as on 31-07-2024
- Company Age 15 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit -16.35%
(FY 2023)
- Ebitda -16.67%
(FY 2023)
- Net Worth 3.86%
(FY 2023)
- Total Assets %
(FY 2023)
About Denvax Cellular Therapies
The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.10 Cr and a paid-up capital of Rs 1.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Arun Mehra, Anita Mehra, Sanjiv Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U85191DL2009PTC192776
- Company No.
192776
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
31 Jul 2009
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Denvax Cellular Therapies?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Mehra  | Director | 31-Jul-2009 | Current |
| Anita Mehra | Director | 31-Jul-2009 | Current |
| Sanjiv Jain | Director | 31-Jul-2009 | Current |
| Anju Jain | Director | 31-Jul-2009 | Current |
Financial Performance of Denvax Cellular Therapies.
Denvax Cellular Therapies Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 16.35% decrease in profit. The company's net worth moved up by a moderate rise of 3.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Denvax Cellular Therapies?
In 2023, Denvax Cellular Therapies had a promoter holding of 97.64% and a public holding of 2.36%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Apac Biotech Private LimitedActive 14 years 4 daysArun Mehra, Anita Mehra and 2 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Denvax Cellular Therapies?
Unlock and access historical data on people associated with Denvax Cellular Therapies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Denvax Cellular Therapies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Denvax Cellular Therapies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
